摘要
【目的】观察同步放化疗联合重组人血管内皮抑制素(恩度)治疗III期巨块型宫颈癌的临床疗效。【方法】将50例III期巨块型宫颈癌患者随机分为2组:对照组25例,恩度组25例。对照组:采用8MV/X直线加速器线盆腔外放疗+252锎中子后装放疗。顺铂30mg/m2静脉滴注,1次/周,共6周,放疗结束后,行紫杉醇135mg/m2+顺铂80mg/m2辅助化疗2周期。恩度组:放化疗方法与对照组相同,在放疗开始每周1次恩度75mg/120h持续微量泵泵入,共6周。【结果】近期临床疗效:对照组CR11例,PR9例,SD5例,有效率80.0%;恩度组CR15例,PR8例,SD2例,有效率92.0%,恩度组的有效率显著高于对照组,差异具有统计学意义(P<0.05)。恩度组3年生存率68.0%(17/25),对照组3年生存率52.0%(13/25),恩度组3年生存率显著高于对照组,差异具有统计学意义(P<0.05)。【结论】恩度联合同步放化疗可提高III期巨块型宫颈癌的疗效,而不良反应没有增加。
[Objective] To investigate the efficacy of the Endostar combined with co-chemoradiotherapy to stage ]I bulky cervical cancer. [ Methods ] Fifty cases with stage III bulky cervical cancer were divided randomly into two groups, co-chemoradiotherapy group （Control group） and Endostar combined with co-chemoradiotherapy group （Endostar group）. There was no difference of co-chemoradiotherapy and chemotherapy after radiotherapy between the two groups. The Endostar cases who accepted Endostar during the radiation,according to 75 mg endostar was solved in mini transfer pump administered by continuous infusion for 120 hours. These reagents were given for 6 weeks. [ Results] In control group CR 11 cases, PR 9 cases, SD 5 case, the total response rate was 80.0%. In Endostar group CR 15 cases, PR 8 cases, SD2 cases, the total response rate was 92.0%.The total response rate of Endostar group was higher than that of the control group. There was significant difference between the two groups. Three year survival rate was 68.0% and 52.0% in Endostar group and control group respectively. There was significant difference between the two groups. [Conclusion ] The Endostar combined with co-chemoradiotherapy can improve the efficacy of the stage III bulky cervical cancer, and the adverse effects was not raised.
出处
《武警后勤学院学报（医学版）》
CAS
2013年第3期178-181,共4页
Journal of Logistics University of PAP（Medical Sciences）
基金
中华国际医学交流基金会先声抗肿瘤治疗专项科研基金
全国临床医药研究专项基金(L2012065)
